AMELIA FASCIANO: Open Payments
NPI 1083189054 · PARAMUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$736 in 11 payments from 8 companies in 2025. Trend: 2023 $435 · 2024 $789 · 2025 $736
Food & beverage: $736
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $199 |
| Otsuka America Pharmaceutical, Inc. | 2 | $127 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $108 |
| Aimmune Therapeutics, Inc. | 1 | $103 |
| Lilly USA, LLC | 1 | $72 |
| Indivior Inc. | 1 | $71 |
| Braeburn Inc. | 2 | $31 |
| Alkermes, Inc. | 1 | $25 |
Products named: REXULTI, BREZTRI, CAPLYTA, ZENPEP, AIRSUPRA, MOUNJARO, SUBLOCADE, BRIXADI.
Industry payments across NJ — which companies pay providers there.
